Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06824051 · ClinicalTrials.gov registry record · Phase 1
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight
A Phase 1 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 4
- Study locations
NCT06824051 is a Phase 1 study of Obesity and Overweight that has completed, run by Eli Lilly and Company. The registered enrollment target is 120 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT06824051, a Phase 1 study of Obesity and Overweight, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 4
- Study locations
Study Summary
The main purpose of this study is to see how orforglipron affects the amount of body fat compared with placebo in participants with obesity or overweight. Participation in the study will last approximately 8 months.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Orforglipron
Study Locations (4)
Florida
- Clinical Pharmacology of Miami - Miami
Minnesota
- Axis - Dilworth
Ohio
- Ohio Clinical Trials - Columbus
Texas
- Endeavor Clinical Trials - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-02-17 |
| Est. Completion | 2026-01-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06824051
The ClinicalTrials.gov registry entry for NCT06824051 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (85% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06824051 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Minnesota, Ohio.
Frequently Asked Questions
What is clinical trial NCT06824051 about?
NCT06824051 is a clinical study titled "A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight". The main purpose of this study is to see how orforglipron affects the amount of body fat compared with placebo in participants with obesity or overweight. Participation in the study will last approximately 8 months.
What is the current status of trial NCT06824051?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2025-02-17. Estimated completion is 2026-01-26.
What conditions does trial NCT06824051 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT06824051?
The interventions under investigation include: Placebo (DRUG), Orforglipron (DRUG).
Who is sponsoring clinical trial NCT06824051?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06824051 being conducted?
This trial has 4 study locations across Florida, Minnesota, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.